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Abstract

Key Points

IMPORTANCE For some patients receiving warfarin, adding aspirin (acetylsalicylic acid) increases
bleeding risk with unclear treatment benefit. Reducing excess aspirin use could be associated with
improved clinical outcomes.

Question Is it possible to reduce excess
aspirin (acetylsalicylic acid) use among
patients treated with warfarin, and is
reducing excess aspirin use associated

OBJECTIVE To assess changes in aspirin use, bleeding, and thrombosis event rates among patients

with improved clinical outcomes?
Findings This multicenter quality

treated with warfarin.

improvement study of 6738 adults

DESIGN, SETTING, AND PARTICIPANTS This pre-post observational quality improvement study

taking warfarin for atrial fibrillation

was conducted from January 1, 2010, to December 31, 2019, at a 6-center quality improvement

and/or venous thromboembolism

collaborative in Michigan among 6738 adults taking warfarin for atrial fibrillation and/or venous

without an apparent indication for

thromboembolism without an apparent indication for concomitant aspirin. Statistical analysis was

concomitant aspirin found that an

conducted from November 26, 2020, to June 14, 2021.

anticoagulation clinic–based aspirin
deimplementation intervention was

INTERVENTION Primary care professionals for patients taking aspirin were asked whether an

associated with a significant

ongoing combination aspirin and warfarin treatment was indicated. If not, then aspirin was

acceleration of a preexisting decrease in

discontinued with the approval of the managing clinician.

excess aspirin use. Reducing aspirin use
was associated with significantly less

MAIN OUTCOMES AND MEASURES Outcomes were assessed before and after intervention for the

bleeding and health care use; no

primary analysis and before and after 24 months before the intervention (when rates of aspirin use

increase in thrombotic outcomes was

first began to decrease) for the secondary analysis. Outcomes included the rate of aspirin use,

observed.

bleeding, and thrombotic outcomes. An interrupted time series analysis assessed cumulative
monthly event rates over time.

Meaning This study suggests that it is
possible to reduce aspirin use without a
clear indication and that this effort may

RESULTS A total of 6738 patients treated with warfarin (3160 men [46.9%]; mean [SD] age, 62.8
[16.2] years) were followed up for a median of 6.7 months (IQR, 3.2-19.3 months). Aspirin use

be associated with improved clinical
outcomes.

decreased slightly from a baseline mean use of 29.4% (95% CI, 28.9%-29.9%) to 27.1% (95% CI,
26.1%-28.0%) during the 24 months before the intervention (P < .001 for slope before and after 24
months before the intervention) with an accelerated decrease after the intervention (mean aspirin
use, 15.7%; 95% CI, 14.8%-16.8%; P = .001 for slope before and after intervention). In the primary
analysis, the intervention was associated with a significant decrease in major bleeding events per

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

month (preintervention, 0.31%; 95% CI, 0.27%-0.34%; postintervention, 0.21%; 95% CI,
0.14%-0.28%; P = .03 for difference in slope before and after intervention). No change was observed
in mean percentage of patients having a thrombotic event from before to after the intervention
(0.21% vs 0.24%; P = .34 for difference in slope). In the secondary analysis, reducing aspirin use
(starting 24 months before the intervention) was associated with decreases in mean percentage of
patients having any bleeding event (2.3% vs 1.5%; P = .02 for change in slope before and after 24
months before the intervention), mean percentage of patients having a major bleeding event (0.31%
(continued)
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Abstract (continued)

vs 0.25%; P = .001 for change in slope before and after 24 months before the intervention), and
mean percentage of patients with an emergency department visit for bleeding (0.99% vs 0.67%;
P = .04 for change in slope before and after 24 months before the intervention), with no change in
mean percentage of patients with a thrombotic event (0.20% vs 0.23%; P = .36 for change in slope
before and after 24 months before the intervention).
CONCLUSIONS AND RELEVANCE This quality improvement intervention was associated with an
acceleration of a preexisting decrease in aspirin use among patients taking warfarin for atrial
fibrillation and/or venous thromboembolism without a clear indication for aspirin therapy.
Reductions in aspirin use were associated with reduced bleeding. This study suggests that an
anticoagulation clinic–based aspirin deimplementation intervention can improve guidelineconcordant aspirin use.
JAMA Network Open. 2022;5(9):e2231973. doi:10.1001/jamanetworkopen.2022.31973

Introduction
Aspirin (acetylsalicylic acid) is used for the primary prevention of coronary artery disease,1,2 for stable
ischemic heart disease,3 for peripheral arterial disease,4,5 and/or for the secondary prevention of
stroke after a noncardioembolic stroke or transient ischemic attack.6,7 Aspirin is appropriately
combined with warfarin for some patients with atrial fibrillation or venous thromboembolism after
acute coronary syndromes or percutaneous coronary interventions8,9 and for some patients with
mechanical heart valves.10-12 For most other patients, evidence suggests that a combination of
warfarin and aspirin therapy likely does more harm than good by increasing bleeding events without
a clear reduction in thrombotic outcomes.13-19 Combination therapy with warfarin plus aspirin is
estimated to result in a 1.5- to 2.0-fold risk of major bleeding compared with warfarin alone.18 For
every 1000 patients, combination therapy may add 10 to 20 major bleeding events and 1 to 2 deaths
per year compared with warfarin monotherapy.19 Many patients appear to be receiving aspirin even
when the anticipated risk exceeds the benefit.
Recognizing the potential harm of combination warfarin and aspirin therapy, guidelines for atrial
fibrillation with stable coronary artery disease,9 stroke,6 peripheral arterial disease,4,5 and aspirin for
primary prevention20 suggest that warfarin monotherapy may be sufficient for most patients. A
recent study confirmed the adverse effects of warfarin plus aspirin in a large registry-based cohort of
patients receiving warfarin without a history of valve replacement or recent myocardial infarction
who were followed up by the Michigan Anticoagulation Quality Improvement Initiative (MAQI2).13
Patients taking aspirin plus warfarin had significantly higher bleeding rates but a similar rate of
thrombotic outcomes.
Given the high rate of inappropriate aspirin use and associated harms among patients treated
with warfarin, each of the 6 clinical sites of the MAQI2 implemented a common intervention to
reduce high-risk aspirin use. We sought to evaluate the preintervention and postintervention
proportion of patients receiving aspirin without a clear indication. We also sought to evaluate the
association of the intervention with clinical outcomes.

Methods
Study Design and Participants
The MAQI2 is a collaborative of 6 outpatient anticoagulation clinics throughout Michigan that
includes both academic and community practices21; all forms of health insurance are accepted. These
anticoagulation clinics represent rural and urban practices, with patient censuses ranging from
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hundreds to more than 5000 (eTable in the Supplement). Each participating site used a tailored
screening process to identify adults receiving warfarin for atrial fibrillation and/or venous
thromboembolism who were also receiving concomitant aspirin that may have been inappropriate.
Potential inappropriate aspirin use was assessed based on an agreed-on set of criteria. Specifically,
patients targeted for review of their ongoing aspirin use were adults without a history of coronary
artery disease, myocardial infarction, any percutaneous coronary intervention, coronary artery
bypass grafting, peripheral arterial disease, mechanical valve replacement, or use of left ventricular
assist devices who were taking warfarin for atrial fibrillation or venous thromboembolism. Sites were
encouraged to further limit patients targeted for review based on their institutional practice patterns
(eg, some sites did not include patients with a history of stroke, heart transplant, or antiphospholipid
syndrome). Site-specific screening processes are summarized in the eTable in the Supplement. This
study follows the Standards for Quality Improvement Reporting Excellence (SQUIRE) reporting
guideline and was approved by the institutional review board at all participating centers before data
collection. A waiver of informed consent was granted by the institutional review boards at each
participating center and the coordinating center because this study was a quality
improvement project.
If screening found that a patient’s indication for aspirin use was unclear or potentially
inappropriate, communication with the patient’s primary care physician or managing specialist
ensued to alert them to their patient’s use of aspirin and discuss the need for therapy. All patient
management decisions were deferred to the managing physician, but input was provided by the
anticoagulation clinic staff. To allow for local tailoring of the intervention, the various sites differed in
the personnel carrying out the intervention, how technology was used, and how clinicians were
contacted.
The quality improvement interventions were enacted between October 1, 2017, and June 30,
2018; all analyses used site-specific dates of the intervention to compare preintervention and
postintervention data. We referred to the period 96 months prior to intervention to 24 months prior
to intervention as the historical period, the period from 24 months prior to the intervention until the
intervention as the preintervention period, and the 24 months after the intervention as the
postintervention period. Data used for this analysis were collected from January 1, 2010, through
December 31, 2019.

Data Collection and Outcome Measures
Patients were followed up from the time of MAQI2 enrollment until they were discharged from the
anticoagulation clinic, they were lost to follow-up, the end of the study period, or death. Given the
broad catchment of our hospital network with comprehensive follow-up, we do not think that the
study findings were associated with patients entering or leaving the registry. Data collection was
performed by trained abstractors using standardized data collection forms. Through combined use
of wide-ranging validation rules during data entry and an automated program that identifies missing
information and prompts for completion and correction, there were no missing data in the important
variables used in the analysis. Body mass index could not be calculated for all patients owing to
missing data in the primary medical records, but body mass index was not used in the analysis of
aspirin use or clinical outcomes. Random medical record audits were performed by the coordinating
center to ensure that the abstracted data matched the primary electronic medical records.21
Data collected at study enrollment included patient demographic characteristics, comorbidities,
bleeding and thrombosis risk factors, histories of bleeding or thrombosis, and concomitant
medications (including antiplatelet therapies other than aspirin). The HAS-BLED (hypertension,
abnormal kidney or liver function, stroke, bleeding history or predisposition, labile international
normalized ratio, elderly, drugs or alcohol concomitantly) score22 and the CHA2DS2-VASc (congestive
heart failure, hypertension, age ⱖ75 years, diabetes, prior stroke or transient ischemic attack,
vascular disease, age 65-74 years, and sex category [female]) risk score23 were calculated for each
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patient at the time of study enrollment, with the HAS-BLED score modified to exclude the labile
international normalized ratio.
Indications for aspirin use were assessed at enrollment for the preintervention cohort and
assessed at either enrollment or the first follow-up after the implementation of the intervention for
the postintervention cohort. Our primary outcome was the rate of inappropriate aspirin use over
time. Inappropriate aspirin use was assessed by each site based on their assessment of patients who
might benefit from review by their physician.
Our secondary outcomes were rates of any bleeding, major bleeding as defined by the
International Society on Thrombosis and Haemostasis,24 nonmajor bleeding (defined as any bleeding
that did not meet the definition of major bleeding), and thrombosis. Thrombotic outcomes included
ischemic or embolic stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis,
intracardiac thrombus, or other or unknown clot. We also assessed rates of emergency department
visits and hospitalizations related to bleeding.

Statistical Analysis
Statistical analysis was conducted from November 26, 2020, to June 14, 2021. Initial review of aspirin
use demonstrated a decrease starting approximately 24 months prior to the intervention. Therefore,
in addition to our primary analysis comparing outcomes before and after the date of the aspirindeprescribing intervention, we also conducted a secondary analysis comparing outcomes before and
after the initial time of aspirin decrease (24 months prior to the aspirin-deprescribing intervention).
Given the dynamic nature of clinic-level patient volumes, risk profiles over time, and medication
use, we used monthly aggregated data as the unit of analysis. Thus, the outcomes represent the
percentage of patients treated with warfarin who experienced an event each month.
To examine the changing percentage of patients taking aspirin without a clear indication who
experienced an outcome event, we conducted interrupted time series analyses by way of a linear
regression model. This model contained binary variables indicating before or after the intervention
representing the interruption. From this model, we could then estimate the trajectory of the
percentage of patients in the preintervention and postintervention periods separately, to test
whether those trajectories differed. A secondary interrupted time series analysis used 24 months
prior to the aspirin-deprescribing intervention (the time when aspirin use began to decrease) as the
interruption time point. Given the nature of monthly aggregated data, comparisons of event rates
were not adjusted for patient-level data. A 2-sided P < .05 was considered statistically significant for
all comparisons. All statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc) and
Stata, version 16 (StataCorp LLC).

Results
A total of 6738 patients receiving warfarin without an indication for aspirin were followed up by the
MAQI2 (3160 men [46.9%; 95% CI, 45.7%-48.1%]; mean [SD] age, 62.8 [16.2] years) for a median of
6.7 months (IQR, 3.2-19.3 months). Most patients (3714 [55.1%]) received warfarin for anticoagulation
for venous thromboembolic disease (Table).

Outcomes Associated With Multisite Deprescribing Intervention
Overall aspirin use without an indication was reduced by nearly 50% after the aspirin-deprescribing
intervention, from 28.9% (95% CI, 28.4%-29.4%) before the intervention to 15.7% (95% CI,
14.7%-16.6%) after the intervention (Figure 1; eFigure 1 in the Supplement). During the historical
period 1, at 96 months prior to the intervention to 24 months prior to the intervention, the
percentage of patients receiving aspirin per month was unstable but generally around 30%,
especially as we approached the preintervention period (at 48 months prior to the intervention, 297
of 987 [30.1%; IQR, 28.9%-31.4%]; at 36 months prior to the intervention, 312 of 1019 [30.6%; IQR,
29.4%-31.9%]) (Figure 1). Starting at 24 months prior to our intervention, the preintervention period,
JAMA Network Open. 2022;5(9):e2231973. doi:10.1001/jamanetworkopen.2022.31973 (Reprinted)
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Table. Characteristics of Study Cohort
Characteristic

Patients, No. (%) (N = 6738)

Sex
Male

3160 (46.9)

Female

3578 (53.1)

Age at enrollment, y
Mean (SD)

62.8 (16.2)

Median (IQR)

64.3 (52.2-75.0)

Weight <50 kg

177/6483 (2.7)

BMI >30

3062/6288 (48.7)

Alcohol or drug use

329 (4.9)

Tobacco use
Former

1754 (26.0)

Current

569 (8.4)

HAS-BLED score at enrollment
Mean (SD)a

2.0 (1.3)

Median (IQR)

2.0 (1.0-3.0)

CCI at enrollment
Mean (SD)

3.2 (1.9)

Median (IQR)

3.0 (2.0-5.0)

CHA2DS2-VASc risk score at enrollment, mean (SD)
Mean (SD)

2.2 (1.5)

Median (IQR)

2.0 (1.0-3.0)

Indication at enrollment
Atrial fibrillation or atrial flutter only

2955 (43.9)

Deep vein thrombosis or pulmonary embolism only

3714 (55.1)

Both

69 (1.0)

Comorbidities at enrollment
Cancer

1355 (20.1)

Congestive heart failure

753 (11.2)

Chronic liver disease

149 (2.2)

Chronic kidney disease

736 (10.9)

Diabetes

1359 (20.2)

History of falls

222 (3.3)

Hypercoagulable state

224 (3.3)

Hypertension

3872 (57.5)

Seizure disorder

96 (1.4)

History of bleeding or thrombosis
Bleeding
≤30 d

166 (2.5)

>30 d

144 (2.1)

Diathesis

43 (0.6)

Prior gastrointestinal bleeding

237 (3.5)

History of embolism (not deep vein thrombosis or pulmonary embolism)

63 (0.9)

Prior deep vein thrombosis or pulmonary embolism

1145 (17.0)

Aspirin use at enrollment
Aspirin
≤100 mg

1441 (21.4)

>100 mg

262 (3.9)

Follow-up, mo
Mean (SD)

16.4 (21.6)

Median (IQR)

6.7 (3.2-19.3)
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transient ischemic attack, vascular disease, age 65-74
years, sex category (female); CCI, Charlson
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abnormal kidney or liver function, stroke, bleeding
history or predisposition, labile international
normalized ratio, elderly, drugs or alcohol
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normalized ratio.
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there was a small but significant decrease in mean aspirin use (27.1%; 95% CI, 26.1%-28.0%)
compared with a mean baseline use of 29.4% (95% CI, 28.9%-29.9%); this decrease was statistically
significantly stronger than during the historical period (P < .001 for the slope before and after 24
months before the intervention). After the intervention into the postintervention period, a
significantly accelerated decrease in aspirin use was observed (mean aspirin use, 15.7%; 95% CI,
14.8%-16.5%). This decrease’s trajectory was steeper than that of the preintervention period’s
trajectory (P = .001 for the slope before and after the intervention period) (Figure 1). Therefore,
although aspirin use was decreasing prior to the intervention, an accelerated decrease was
associated with the intervention.
When comparing the historical and preintervention periods with the postintervention period,
we observed a reduction in the mean percentage of patients with a major bleeding event (0.31% vs
0.21%; P = .03 for difference in slope before and after intervention; Figure 2) without a significant
change in the mean percentage of patients with a thrombotic event (0.21% vs 0.24%; P = .34 for
difference in slope before and after intervention; Figure 3). Before the intervention, a mean of 0.31%
of patients (95% CI, 0.27%-0.34%) had a major bleeding event per month compared with a mean
of 0.21% of patients (95% CI, 0.14%-0.28%) after the intervention (32.3% risk reduction; 1 major
bleeding event prevented for every 1000 patients stopping aspirin). There was no statistically
significant difference in the mean percentage of patients having any postintervention bleeding event
(2.2% vs 1.3%; P = .12 for difference in slope before and after intervention; eFigure 2 in the

Figure 1. Percentage of Warfarin-Treated Patients Taking Aspirin Without an Apparent Indication by Month
–24 mo

Intervention

35

Patients taking aspirin/mo, %

30
25

Historical mean: 29.4%

20
Preintervention
mean: 27.1%

15
10
5

Historical vs preintervention: P <.001
Preintervention vs postintervention: P =.001
Historical vs postintervention: P <.001

Postintervention
mean: 15.7%
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0
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Time, mo

At baseline, 29.4% of the patient population was
taking warfarin and aspirin without a history of
coronary artery disease, myocardial infarction,
percutaneous coronary intervention, coronary artery
bypass grafting, peripheral arterial disease, heart valve
replacement, use of left ventricular assist device, heart
transplant, or (at some centers) a history of stroke or
antiphospholipid syndrome. Starting 24 months
before the intervention, a significant decrease in
aspirin use was observed. After the intervention, a
further significant decrease in aspirin use was
achieved, with a mean postintervention rate of aspirin
use of 15.7%, compared with 27.1% immediately before
the intervention. P values compare the slopes of the
regression lines.

Figure 2. Percentage of Warfarin-Treated Patients Taking Aspirin Without an Apparent Indication by Month
Who Experienced Major Bleeding
Intervention P =.03
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Supplement), mean percentage of patients having a nonmajor bleeding event (1.9% vs 1.1%; P = .37
for difference in slope before and after intervention; eFigure 3 in the Supplement), mean percentage
of patients having an emergency department visit for bleeding (0.94 vs 0.57; P = .35 for difference
in slope before and after intervention; eFigure 4 in the Supplement), and mean percentage of
patients admitted for bleeding (0.58% vs 0.35%; P = .97 for difference in slope before and after
intervention; eFigure 5 in the Supplement).

Outcomes Associated With Reduction in Aspirin Use
To evaluate the clinical association of lower aspirin use with overall outcomes, we explored clinical
outcomes before aspirin use began to decrease (historical period) compared with after aspirin use
began to decrease (preintervention and postintervention periods, starting 24 months before the
aspirin-deprescribing intervention; Figure 1) because this was the time point when aspirin use began
to decrease across all sites. Reducing aspirin use was associated with a reduction in the mean
percentage of patients having a bleeding event (2.3% vs 1.5%; P = .02 for difference in slope before
and after 24 months before the intervention; Figure 4). It was also associated with a reduction in the
mean percentage of patients with a major bleeding event (0.31% vs 0.25%; P = .001 for difference
in slope before and after 24 months before the intervention; eFigure 6 in the Supplement) and a
reduction in the mean percentage of patients having an emergency department visit for bleeding
(0.99% vs 0.67%; P = .04 for difference in slope before and after 24 months before the intervention;

Figure 3. Percentage of Warfarin-Treated Patients Taking Aspirin Without an Apparent Indication by Month
Who Experienced Thrombotic Events
Intervention P =.34
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There was no statistically significant change in
thrombotic events per month during the 24 months
after the intervention compared with before the
intervention. P value compares the slopes of the
regression lines.

Figure 4. Percentage of Patients Treated With Warfarin Taking Aspirin Without an Apparent Indication
by Month Who Experienced Any Bleeding
–24 mo P =.02
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eFigure 7 in the Supplement). We did not observe a reduction in the mean percentage of patients
with a nonmajor bleeding event (2.0% vs 1.3%; P = .13 for difference in slope before and after 24
months before the intervention; eFigure 8 in the Supplement) or the mean percentage of patients
with an admission for bleeding (0.62% vs 0.38%; P = .57 for difference in slope before and after 24
months before the intervention; eFigure 9 in the Supplement). The mean percentages of patients
with a thrombotic event were similar before and after reducing excess aspirin use (0.20% vs 0.23%;
P = .36 for difference in slope before and after 24 months before the intervention; eFigure 10 in the
Supplement).

Discussion
Although inappropriate aspirin use among patients treated with warfarin has been recognized as a
problem,13 little is known about how to reduce excess aspirin use among this high-risk population. In
this multicenter, anticoagulation clinic–based quality improvement project, the intervention was
associated with a significant reduction in excess aspirin use among patients treated with warfarin for
atrial fibrillation and/or venous thromboembolism with no apparent indication for aspirin. After this
deprescribing intervention, we observed a reduction in major bleeding events with no increase in
thrombotic outcomes. Furthermore, the decrease in aspirin use that began approximately 2 years
prior to our intervention was associated with a significant reduction in any bleeding, major bleeding,
and emergency department visits for bleeding. These findings highlight the need for greater aspirin
stewardship among patients receiving warfarin for anticoagulation. Our successful intervention
across multiple health systems, with different patient populations and clinical structures, could serve
as a national model for reducing excess aspirin use.
Our intervention was associated with a significant reduction in major bleeding (Figure 1).
However, without a control group, it was not possible to know whether the intervention directly
resulted in reduced bleeding outcomes. A previous study of our registry data found that concomitant
aspirin and warfarin therapy was associated with 1 additional major bleeding event for every 36
patients receiving combination therapy instead of warfarin monotherapy.13 Accordingly, it could be
anticipated that this intervention would have the potential for a significant clinical association with
bleeding outcomes. Although event rates decreased after the intervention for all studied bleeding
outcomes, we did not observe a significant postintervention reduction in any bleeding, nonmajor
bleeding, or health care use (eFigures 2-5 in the Supplement). It is possible that our ability to detect a
statistical difference was limited by the length of follow-up, which affected statistical power. When
we look at the longer time period represented by our 24-month pre-post intervention analysis, the
longer follow-up period allowed for the detection of more postintervention bleeding events and,
therefore, for more statistical power (Figure 4; eFigure 6 in the Supplement).
One major challenge to a multicenter aspirin-deprescribing intervention is reaching consensus
on when aspirin use is unnecessary. We focused on patient populations in which the clinicians
thought there was broad agreement that concomitant use of aspirin with warfarin was generally not
needed. In addition, all management decisions were left to clinicians who were directly involved in
the care of the patient and able to engage in shared decision-making.
The second challenge to reducing excess aspirin use is developing a systematic approach to
reducing excess aspirin use. Anticoagulation clinics are commonly used to manage the millions of
patients in the US currently treated with warfarin; they are often run by physicians, pharmacists, and
nurses with expertise in anticoagulation and antiplatelet therapies.20 An anticoagulation clinic–
based intervention is a logical starting place for such an initiative to improve medication safety.25 The
anticoagulation clinic health care professionals’ knowledge of anticoagulation therapies and their
frequent interactions with patients and their physicians could facilitate meaningful changes.
Although the intervention required an initial investment in time and effort, this effort demonstrated
its worth through the reduction in excess aspirin use. A meticulous medication reconciliation process
should be incorporated during anticoagulation clinic enrollment because this is an opportune time
JAMA Network Open. 2022;5(9):e2231973. doi:10.1001/jamanetworkopen.2022.31973 (Reprinted)
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to address potentially unnecessary aspirin use; a previous study found that nearly one-third of
patients receiving warfarin were using aspirin with warfarin despite not having a clear need for
such therapy.13
Not all patients receiving warfarin are followed up at anticoagulation clinics. Although the
expertise of the health care professionals at our anticoagulation clinics was integral to the success of
this effort, this effort could readily be adapted to other settings. Specifically, a similar approach could
be used by primary care physicians and subspecialty clinics to reach a broader patient population.
Resources developed by the MAQI2 for our intervention are available online26 for other centers
interested in adapting this work. Other centers have similarly been able to implement similar
interventions27,28; this is one of the first studies to report on clinical outcomes, to our knowledge.
Our data show that there was a significant decrease in aspirin use about 24 months before our
intervention (Figure 1). It is not clear whether this decrease was associated with prior quality
improvement efforts or indirect outcomes of our preparation for this intervention. The European
Society of Cardiology and the 2016 US Preventive Services Task Force guidelines on aspirin use for
primary prevention1 immediately predated this observed decrease, and several pivotal trials on
aspirin for primary prevention followed this observation.29 Nevertheless, with the start of our
intervention, the rate of observed decrease in aspirin use significantly increased, suggesting that the
intervention may be partially responsible for the improved clinical outcomes (Figure 1).
Further research is needed to determine whether deprescribing aspirin for patients receiving
direct oral anticoagulants is similarly effective and to confirm our study findings, ideally with a control
group. It is also unclear why so many patients treated with warfarin were receiving concomitant
aspirin without a strong reason for it. In many situations, clinicians (1) may be unaware of the
guidelines or data, (2) may favor antiplatelet therapy for patients with numerous or poorly controlled
vascular risk factors, (3) may be unclear as to who is managing the aspirin use when multiple clinicians
and subspecialists are involved (primary care, hematology, general cardiology, interventional
cardiology, electrophysiology, and/or vascular surgery), and (4) may not discontinue aspirin use
(often for primary prevention) with warfarin initiation. Given that aspirin is not a prescription
medication, it could be postulated that clinicians may not always be aware that patients are taking
aspirin, which is a barrier to aspirin-deprescribing efforts.
Although we did not directly ask patients why they were taking aspirin, we excluded many
patient groups that may have been taking aspirin for secondary prevention. Accordingly, we assumed
that many patients were taking aspirin for primary prevention. In fact, aspirin is used for the primary
prevention of cardiovascular disease by 25% to 45% of US adults older than 40 years.30-32 A prior
retrospective review16 suggested that aspirin was not discontinued for about 28% of patients after
they developed an indication for warfarin, which seems to be the case for many of the patients in our
study. The American College of Cardiology/American Heart Association guidelines20 and US
Preventive Services Task Force guidelines33 no longer support aspirin use for many of these patients,
even if they were not receiving concomitant warfarin.

Limitations
Our study has several limitations. A registry-based study has inherent limitations, including the
potential for missing data and the inability to infer causation without randomization. All aspirin use
was per patient report, and it is possible that aspirin was discontinued and later resumed without
changes in the medical record. The patients being followed up at experienced anticoagulation clinics
that regularly engage in quality improvement activities may limit the generalizability of our study.
Although the clinical data were collected from several diverse institutions, the study was also
geographically limited to 1 state. Data on myocardial infarction were not well captured because this
outcome was not the primary intent of the warfarin quality improvement registry. Patients receiving
medical care for outcome events outside our hospital network may not have been well captured if
they were not reported back to the anticoagulation clinic staff. Finally, the overall event rates were
low, potentially limiting the statistical power of our study.
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Conclusions
Our multicenter, anticoagulation clinic–based quality improvement initiative successfully
deprescribed unnecessary aspirin for patients receiving long-term warfarin therapy. Reducing aspirin
use was associated with reduced bleeding outcomes without an observed increase in thrombotic
outcomes. This study emphasizes the importance of appropriate aspirin stewardship for patients
receiving warfarin and serves as a quality improvement deprescribing model for other
health systems.
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